دورية أكاديمية
[Clinical value of (125)I radioactive seed implantation plus transcatheter arterial chemoembolization combined with radiofrequency ablation in treating patient with sub-capsular hepatocellular carcinoma].
| العنوان: | [Clinical value of (125)I radioactive seed implantation plus transcatheter arterial chemoembolization combined with radiofrequency ablation in treating patient with sub-capsular hepatocellular carcinoma]. |
|---|---|
| المؤلفون: | Fang SJ; Department of Interventional Radiology, Lishui Hospital of Zhejiang University, the Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Municipal Central Hospital, Lishui 323000, China., Gao RJ, Zheng LY, Zhao ZW, Fan XX, Song JJ, Zhang DK, Wu FZ, Ji JS |
| المصدر: | Zhonghua yi xue za zhi [Zhonghua Yi Xue Za Zhi] 2018 Dec 18; Vol. 98 (47), pp. 3853-3857. |
| نوع المنشور: | Journal Article |
| اللغة: | Chinese |
| بيانات الدورية: | Publisher: Zhonghua yi xue hui Country of Publication: China NLM ID: 7511141 Publication Model: Print Cited Medium: Print ISSN: 0376-2491 (Print) Linking ISSN: 03762491 NLM ISO Abbreviation: Zhonghua Yi Xue Za Zhi Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Beijing : Zhonghua yi xue hui Original Publication: Beijing : Zhonghua yi xue hui. |
| مواضيع طبية MeSH: | Carcinoma, Hepatocellular* , Chemoembolization, Therapeutic* , Liver Neoplasms*, Adult ; Aged ; Catheter Ablation ; Combined Modality Therapy ; Female ; Humans ; Iodine Radioisotopes ; Male ; Middle Aged ; Radiofrequency Ablation ; Treatment Outcome |
| مستخلص: | Objective: To analyze the clinical efficacy and safety of (125)I radioactive seed implantation in the treatment of sub-capsular hepatocellular carcinoma (sub-HCC) with sequential radiofrequency ablation and transcatheter arterial chemoembolization (TACE). Methods: The clinical data of 76 cases with advanced HCC with sub-capsular nodules including 68 males and 8 females, with an average age of (58±9) years, ranging from 33 to 78 years, enrolled in Lishui Central Hospital from January 2010 to December 2016 were collected.The average maximum diameter of tumor is (5.7±2.3) cm, ranging from 3.1 cm to 12.0 cm.The patients were divided into TACE+ RFA group and (125)I + TACE+ RFA group with 38 cases in each group.The overall survival (OS) and progression free survival(PFS) were calculated.The clinical efficiency and adverse events were evaluated. Results: The disease control rate were 84.2%(32/38) in (125)I + TACE+ RFA group and 63.2% (24/38) in TACE+ RFA group, χ(2)=4.34, P = 0.04.The median PFS were 18 months in (125)I + TACE+ RFA group and 11 months in TACE+ RFA group, χ(2)=4.84, P =0.03.The FPS cumulative rate in (125)I + TACE+ RFA group were higher than that in TACE+ RFA group at 6 months (94.7%±3.6% vs 81.3%±6.4%, Z =24.1>2.58, P =0.00), 1 year (89.2%±5.1% vs 40.7%±8.3%, Z =13.3>2.58, P =0.00) and 2 year (55.9%±8.6% vs 29.6%±8.2%, Z =7.2>2.58, P =0.00). The median OS were 42 months in (125)I + TACE+ RFA group and 30 months in TACE+ RFA group, χ(2)=4.76, P =0.029.The survival cumulative rate in (125)I+ TACE+ RFA group were higher than that in TACE+ RFA group at 1 year (92.1%±4.4% vs 83.8%±6.1%, Z =23.5>2.58, P =0.00), 2 year (75.8%±7.0% vs 59.8%±8.4%, Z =12.43>2.58, P =0.00), 3 year (59.0%±8.2% vs 41.7%±8.9%, Z =8.3>2.58, P =0.00), 5 year (34.2%±8.2% vs 18.2%±8.1%, Z =5.5>2.58, P =0.00). In addition, there was no statistical difference in liver function and complications between TACE+ RFA group and (125)I+ TACE+ RFA group. Conclusion: (125)I radioactive seed implantation plus TACE combined with RFA treatment is an effective and safe treatment for sub-capsular hepatocellular carcinoma. |
| معلومات مُعتمدة: | 81573657 National Natural Science Foundation of China; 2013C03010 Science and Technology Major Project of Zhejiang Province; 2016c37101 Social Applied Research Plan Programs of Science and Technology Commission of Zhejiang Province of China |
| فهرسة مساهمة: | Keywords: Drug therapy, combination; Iodine isotopes; Liver neoplasms Local Abstract: [Publisher, Chinese] 目的： 分析(125)I放射性粒子植入联合肝动脉化疗栓塞(TACE)序贯射频消融(RFA)方案治疗包膜下肝癌结节的临床疗效及安全性。 方法： 回顾分析2010年1月至2016年12月丽水市中心医院76例包膜下(肝包膜下<1 cm)中晚期肝癌患者资料。男68例、女8例，年龄33～78(58±9)岁，肿瘤最大径3.1～12.0(5.7±2.3) cm，Child-Pugh A级28例，Child-Pugh B级48例，BCLC B期29例，C期47例。按照治疗方式分为两组，其中38例(TACE＋RFA组)行TACE序贯RFA治疗，38例((125)I＋TACE＋RFA组)在TACE序贯RFA治疗后，行(125)I放射性粒子植入术。分别计算中位生存时间及肿瘤无进展时间，评价两组患者的肿瘤控制有效率及不良反应。 结果： TACE＋RFA组和(125)I＋TACE＋RFA组患者肿瘤有效控制率分别为63.2%(24/38)和84.2%(32/38)，(χ(2)＝4.34, P ＝ 0.04)；肿瘤无进展时间中位值为11和18个月(χ(2)＝4.84， P ＝0.03)，(125)I＋TACE＋RFA组在6个月(94.7%±3.6%比81.3%±6.4%， Z ＝24.1>2.58， P ＝0.00)、1年(89.2%±5.1%比40.7%±8.3%， Z ＝13.3>2.58， P ＝0.00)、2年(55.9%±8.6%比29.6%±8.2%， Z ＝7.2>2.58， P ＝0.00)的累计肿瘤无进展率高于TACE＋RFA组。(125)I＋TACE＋RFA组和TACE＋RFA组的生存时间中位值为42和30个月(χ(2)＝4.76， P ＝0.029)。(125)I＋TACE＋RFA组在1年(92.1%±4.4%比83.8%±6.1%， Z ＝23.5>2.58， P ＝0.00)、2年(75.8%±7.0%比59.8%±8.4%， Z ＝12.43>2.58， P ＝0.00)、3年(59.0%±8.2%比41.7%±8.9%， Z ＝8.3>2.58， P ＝0.00)、5年(34.2%±8.2%比18.2%±8.1%， Z ＝5.5>2.58， P ＝0.00)的累计生存率高于TACE＋RFA组。TACE＋RFA组和(125)I＋TACE＋RFA组术后肝功能、并发症差异无统计学意义。 结论： (125)I放射性粒子植入能够提高TACE序贯RFA治疗中晚期包膜下肝癌的疗效，是一种有效的、安全的中晚期肝癌治疗方法。. |
| المشرفين على المادة: | 0 (Iodine Radioisotopes) |
| تواريخ الأحداث: | Date Created: 20181227 Date Completed: 20190318 Latest Revision: 20190318 |
| رمز التحديث: | 20231215 |
| DOI: | 10.3760/cma.j.issn.0376-2491.2018.47.008 |
| PMID: | 30585029 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 0376-2491 |
|---|---|
| DOI: | 10.3760/cma.j.issn.0376-2491.2018.47.008 |